Graft vs. Host, Chemotherapy Dry Eyes Testimonials
My Life Became Much Better
I had a bone marrow transplant (using marrow donated by my sister) almost 4 years ago, due to leukemia. I ended up with a very bad case of graft vs. host disease, where my sister’s cells were attacking my soft tissue, skin, mouth and eyes. This has left me with very dry eyes. I virtually had no tears and could not open my eyes without a lot of pain. The graft vs. host has since been treated, but my eyes remained very dry. I went on prescription eye drops and permanent eye plugs, but my eyes were still dry. I finally searched the internet and came across TheraLife. I tried the TheraLife Eye Enhanced therapy along with the Fish Oil. After about 2 months of taking the eye therapy, my eyes and my life became much better. I have been faithfully taking TheraLife Eye for about 2 1/2 years now and I honestly don’t know what I would do without this eye therapy.
Thank you for making such a great product.
*Note: Results may vary.*
References
- 1. Socié G, Ritz J. Current issues in chronic graft-vs-host disease. Blood. 2014 Jul 17;124(3):374-84. [PMC free article] [PubMed]
- 2. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01;102(5):1601-5. [PubMed]
- 3.Shimabukuro-Vornhagen A, Liebig T, von Bergwelt-Baildon M. Statins inhibit human APC function: implications for the treatment of GVHD. Blood. 2008 Aug 15;112(4):1544-5. [PubMed]
- 4.Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, Maris MB, Storb R. Graft-vs-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003 Jul 15;102(2):756-62. [PubMed]
- 5. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009 May 02;373(9674):1550-61. [PMC free article] [PubMed]
- 6. Jamil MO, Mineishi S. State-of-the-art acute and chronic GVHD treatment. Int J Hematol. 2015 May;101(5):452-66. [PubMed]
- 7. Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, Jacobsen N, Kolb HJ, Rimm AA, Ringdén O. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990 Jun 15;75(12):2459-64. [PubMed]
- 8. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ. A refined risk score for acute graft-vs-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015 Apr;21(4):761-7. [PMC free article] [PubMed]
- 9. Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E, Good RA, Hoffmann RG, Kay HE, Kersey JH. Risk factors for acute graft-vs-host disease. Br J Haematol. 1987 Dec;67(4):397-406. [PubMed]
- 10. Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute Graft vs Host Disease: A Comprehensive Review. Anticancer Res. 2017 Apr;37(4):1547-1555. [PubMed]